Cyclohexyl Azetidine Derivatives as JAK Inhibitors
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides cyclohexyl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
145 Citations
55 Claims
-
1. A compound of Formula I:
- View Dependent Claims (4, 5, 6, 7, 8, 9, 22, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 51, 52, 53, 54, 55)
-
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are each independently selected from H, —
- CF3, —
CH2Rx, and —
C(CH3)2Rx.
- CF3, —
-
5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein each Rx group is independently selected from ORa1 and NRe1Rf1.
-
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each Ra1, Rc1, Rd1, Re1, and Rf1 is independently selected from H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, Cy2, and —
- C1-3 alkylene-Cy2;
wherein said C1-6 alkyl is optionally substituted by 1, 2, or 3 independently selected Rk groups;
oreach Re1 and Rf1, together with the nitrogen atom to which they are attached, forms a 4-6 membered monocyclic heterocycloalkyl ring;
which is optionally substituted with 1, 2, or 3 independently selected Rm groups.
- C1-3 alkylene-Cy2;
-
7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein each Cy2 is independently selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuran-2-yl, and 1H-imidazol-4-yl, which are each optionally substituted by 1, 2, or 3 independently selected Rm groups.
-
8. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein each Rm is independently selected from halo, hydroxy, C1-4 alkoxy, hydroxyl-C1-4 alkyl, and C1-4 alkoxy-C1-4 alkyl.
-
9. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein each Rk is independently selected from hydroxy, C1-4 alkoxy, hydroxyl-C1-4 alkyl, and C1-4 alkoxy-C1-4 alkyl.
-
22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the 6-membered aromatic ring formed by carbon atom, X, Y, W, Z, and V is selected from:
-
26. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
-
X is N; Y is CR2; W is CR3 or N; Z is CR4; V is CR5; R2, R3, R4, and R5 are each independently selected from H, halo, CN, C1-6 alkyl, C1-6 haloalkyl, Cy, ORa, C(═
O)ORa, and C(═
O)NReRf;
wherein said C1-6 alkyl is optionally substituted by 1, 2, or 3 independently selected Rx groups;each Cy is independently selected from 3-6-membered monocyclic cycloalkyl optionally substituted by 1, 2, or 3 independently selected Rg groups; each Ra, Re, and Rf is, independently, H or C1-6 alkyl;
wherein said C1-6 alkyl is optionally substituted with 1, 2, or 3 independently selected Rh groups;
oreach Re and Rf, together with the nitrogen atom to which they are attached, form a 4-6 membered monocyclic heterocycloalkyl ring; each Rg is independently selected from hydroxy and hydroxyl-C1-4 alkyl; each Rh is independently selected from halo, hydroxy, and C1-4 alkoxy; each Rx group is independently selected from ORa1 and NRe1Rf1; each Ra1, Re1, and Rf1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, Cy2, and —
C1-3 alkylene-Cy2;
wherein said C1-6 alkyl is optionally substituted by 1, 2, or 3 independently selected Rk groups;
oreach Re1 and Rf1, together with the nitrogen atom to which they are attached, forms a 4-6 membered monocyclic heterocycloalkyl ring;
which is optionally substituted with 1, 2, or 3 independently selected Rm groups;each Cy2 is independently selected from 3-6-membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocycloalkyl, and 5-6 membered monocyclic heteroaryl, which are each optionally substituted by 1, 2, or 3 independently selected Rm groups; each Rk is independently selected from hydroxy, C1-4 alkoxy, hydroxyl-C1-4 alkyl, and C1-4 alkoxy-C1-4 alkyl; and each Rm is independently selected from halo, hydroxy, C1-4 alkoxy, hydroxyl-C1-4 alkyl, and C1-4 alkoxy-C1-4 alkyl.
-
-
27. The compound of claim 1, having Formula II:
-
28. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein:
-
R2 is C1-3haloalkyl; R4 is selected from —
CH2OH, —
C(CH3)2OH, and —
CH2NRe1Rf1;Re1 is H or C1-4 alkyl; Rf1 is H, C1-6alkyl, C1-6 haloalkyl, Cy2, or —
C1-2 alkylene-Cy2;
wherein said C1-6 alkyl is optionally substituted with 1 or 2 groups selected from —
OH and —
OCH3;or Re1 and Rf1 together with the nitrogen atom to which they are attached form a 4-6-membered monocyclic heterocycloalkyl ring, which is optionally substituted by one —
F, —
OH, or —
CH2OH group; andCy2 is cyclopropyl, cyclobutyl, 5-membered monocyclic heterocycloalkyl, or 5-membered monocyclic heteroaryl;
each of which is optionally substituted by a —
CH2OH group.
-
-
29. The compound of claim 27, or a pharmaceutically acceptable salt thereof, wherein:
-
R2 is C1-3 haloalkyl; R4 is selected from —
CH2OH, —
C(CH3)2OH, and —
CH2NRe1Rf1 whereinRe1 is H, methyl or ethyl; and Rf1 is H, methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, tert-butyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, cyclopropyl, cyclobutyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-methoxyethyl, 3-methoxypropyl, 2-hydroxy-1-methylethyl, 2-methoxy-1-methylethyl, 2-hydroxy-2-methylethyl, 2-hydroxy-2,2-dimethylethyl, 2,3-dihydroxypropyl, cyclopropylmethyl, (1-(hydroxymethyl)cyclopropyl)methyl, 2-(hydroxymethyl)tetrahydrofuran-2-yl, or 1H-imidazol-4-ylethyl;
orRe1 and Rf1, together with the nitrogen atom to which they are attached, form a group selected from azetidinyl, 3-hydroxy-azetidinyl, 3-fluoro-azetidinyl, pyrrolidinyl, 3-hydroxypyrrolidinyl, 3-fluoropyrrolidinyl, 2-(hydroxymethyl)pyrrolidinyl, and piperidinyl.
-
-
30. The compound of claim 1, having Formula III:
-
31. The compound of claim 1, having Formula IV:
-
32. The compound of claim 1, having Formula V:
-
33. The compound of claim 32, or a pharmaceutically acceptable salt thereof, wherein:
-
R4 is selected from —
CH2OH, —
C(CH3)2OH, —
CH2NRe1Rf1 and C(═
O)NReRf;Re1 is H, methyl or ethyl; Rf1 is H, methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, 2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxy-1-methylethyl, or cyclopropylmethyl;
orRe1 and Re1, together with the nitrogen atom to which they are attached, form a group selected from azetidinyl, 3-hydroxy-azetidinyl, 3-fluoro-azetidinyl, 3-cyano-azetidinyl, pyrrolidinyl, 3-hydroxypyrrolidinyl, 3-fluoropyrrolidinyl, 2-(hydroxymethyl)pyrrolidinyl, piperidinyl, 4-hydroxypiperidinyl, 3-methyloxetan-3-yl, pyrazolyl, and imidazolyl; Re is H or methyl; and Rf is H, methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, or cyclobutyl;
orRe and Rf, together with the nitrogen atom to which they are attached, form a group selected from azetidinyl, 3-hydroxy-azetidinyl, 3-fluoro-azetidinyl, 3-cyano-azetidinyl, pyrrolidinyl, 3-hydroxypyrrolidinyl, 3-fluoropyrrolidinyl, 2-(hydroxymethyl)pyrrolidinyl, and piperidinyl.
-
-
34. The compound of claim 1, having Formula III-A:
-
35. The compound of claim 34, wherein Ra1 is H, methyl or ethyl.
-
37. A compound of claim 1, selected from:
-
{1-(cis-4-{[6-[(dimethylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,1-pyrazol-1-yl]azetidin-3-yl)acetonitrile; {1-(cis-4-{[6-(aminomethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(methylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-1 [6-[(ethylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(isopropylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(cyclopropylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[ethyl(methyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(cyclopropylmethyl)amino]methyl}-2-(tri fluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,1-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-([6-[(cyclobutylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2-hydroxyethyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2-hydroxyethyl)(methyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[ethyl(2-hydroxyethyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; [3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-1-(cis-4-{[6-{[(2,2,2-trifluoroethyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)azetidin-3-yl]acetonitrile; {1-(cis-4-{[6-{[(2-fluoroethyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-({[(1S)-2-hydroxy-1-methylethyl]amino}methyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-({[(1R)-2-hydroxy-1-methylethyl]amino}methyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-({[(2S)-2-hydroxypropyl]amino}methyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-({[(2R)-2-hydroxypropyl]amino}methyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2-hydroxy-2-methylpropyl)amino]triethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(3-hydroxypropyl)amino]methyl-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(2-methoxyethyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(azetidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(3-hydroxyazetidin-1-yl)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(pyrrolidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl)acetonitrile; {1-(cis-4-{[6-1 [(3S)-3-hydroxypyrrolidin-1-yl]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; [3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-1-(cis-4-{[6-({[(2S)-tetrahydrofuran-2-ylmethyl]amino}methyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)azetidin-3-yl]acetonitrile; {1-(cis-4-{[6-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(piperidin-1-ylmethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-1 [(3S)-3-fluoropyrrolidin-1-yl]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl)acetonitrile; {1-(cis-4-{[6-[(propylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2,3-dihydroxypropyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(butylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(isobutylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[butyl(methyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3 [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[(3-fluoroazetidin-1-yl)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[({[1-(hydroxymethyl)cyclopropyl]methyl}amino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; 2-(1-(cis-4-((6-(((2-(1H-imidazol-4-yl)ethyl)amino)methyl)-2-(trifluoromethyl)pyrimidin-4-yl)oxy}cyclohexyl)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile; {1-(cis-4-{[6-{[(3-methoxypropyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2-methoxy-1-methylethyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2-methoxyethyl)(methyl)amino]methyl-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(1-hydroxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; and {1-(cis-4-{[6-[(tert-butylamino)methyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; or a pharmaceutically acceptable salt thereof.
-
-
38. The compound of claim 1, selected from:
-
6-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo [2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-ethyl-2-(trifluoromethyl)pyrimidine-4-carboxamide; {1-(cis-4-{[6-(pyrrolidin-1-ylcarbonyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(2-hydroxy-1,1-dimethylethyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-{[(1-methylcyclopropyl)amino]methyl}-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; 6-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-2-(trifluoromethyl)pyrimidine-4-carbonitrile; {1-(cis-4-{[6-(2-hydroxyethoxy)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(1,2-dihydroxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(1-hydroxyethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(2-hydroxy-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(1-fluoro-1-methylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(2-hydroxy-1,1-dimethylethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-[1-(hydroxymethyl)cyclopropyl]-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[6-(2-hydroxyethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; 6-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N,N-dimethyl-2-(trifluoromethyl)pyrimidine-4-carboxamide; 6-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-ethyl-N-methyl-2-(trifluoromethyl)pyrimidine-4-carboxamide; 6-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-(2-methoxyethyl)-2-(trifluoromethyl)pyrimidine-4-carboxamide; {1-(cis-4-{[6-(2-fluoroethyl)-2-(trifluoromethyl)pyrimidin-4-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl)acetonitrile; {1-(cis-4-{[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-[(methylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-[(dimethylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-(1-hydroxy-1-methylethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(3-hydroxypropyl)amino]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(2-hydroxy-1,1-dimethylethyl)amino]methyl-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl)acetonitrile; {1-(cis-4-{[4-[(cyclopropylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-({[(1S)-2-hydroxy-1-methylethyl]amino}methyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(2-hydroxyethyl)amino]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-({[(1R)-2-hydroxy-1-methylethyl]amino}methyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(cyclopropylmethyl)amino]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-[(cyclobutylamino)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-(azetidin-1-ylmethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-[(3-hydroxyazetidin-1-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; 2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-methyl-6-(trifluoromethyl)isonicotinamide; 2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N,N-dimethyl-6-(trifluoromethyl)isonicotinamide; 2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-(2-hydroxyethyl)-N-methyl-6-(trifluoromethyl)isonicotinamide; 2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-isopropyl-6-(trifluoromethyl)isonicotinamide; 2-[(cis-4-(3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-[(1S)-2-hydroxy-1-methylethyl]-6-(trifluoromethyl)isonicotinamide; 2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-[(1R)-2-hydroxy-1-methylethyl]-6-(trifluoromethyl)isonicotinamide; 2-[(cis-4-(3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-cyclopropyl-6-(trifluoromethyl)isonicotinamide; 2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-cyclopropyl-N-methyl-6-(trifluoromethyl)isonicotinamide; N-(sec-butyl)-2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-6-(trifluoromethyl)isonicotinamide; {1-(cis-4-{[4-[(3-hydroxyazetidin-1-yl)carbonyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; 2-[(cis-4-(3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-N-cyclobutyl-6-(trifluoromethyl)isonicotinamide; 1-[2-[(cis-4-{3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-1-yl}cyclohexyl)oxy]-6-(trifluoromethyl)isonicotinoyl]azetidine-3-carbonitrile; {1-(cis-4-{[4-(morpholin-4-ylmethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-([4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(3S)-3-hydroxypyrrolidin-1-yl]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-[(4-hydroxypiperidin-1-yl)methyl]-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-{[(3-methyl oxetan-3-yl)amino]methyl}-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-{[4-(1H-imidazol-1-ylmethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; {1-(cis-4-1H-pyrazol-1-ylmethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}cyclohexyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile; or a pharmaceutically acceptable salt thereof.
-
-
39. A composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
-
40. A method of inhibiting an activity of JAK1 comprising contacting JAK1 with a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
-
41. A method according to claim 40, wherein said compound, or pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2.
-
42. A method of treating an autoimmune disease, a cancer, a myeloproliferative disorder, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
-
43. A method according to claim 42, wherein said autoimmune disease is a skin disorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, type I diabetes, lupus, inflammatory bowel disease, Crohn'"'"'s disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder.
-
44. A method according to claim 42, wherein said autoimmune disease is rheumatoid arthritis.
-
45. A method according to claim 42, wherein said autoimmune disease is a skin disorder.
-
46. A method according to claim 45, wherein said skin disorder is atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or allergic contact sensitization.
-
48. A method according to claim 42, wherein said cancer is prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi'"'"'s sarcoma, Castleman'"'"'s disease or pancreatic cancer.
-
49. A method according to claim 42, wherein said cancer is lymphoma, leukemia, or multiple myeloma.
-
50. A method according to claim 42, wherein said myeloproliferative disorder is polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast cell disease (SMCD).
-
51. A method according to claim 42, wherein said myeloproliferative disorder is myelofibrosis.
-
52. A method according to claim 42, wherein said myeloproliferative disorder is primary myelofibrosis (PMF).
-
53. A method according to claim. 42, wherein said myeloproliferative disorder is post polycythemia vera myelofibrosis (Post-PV MF).
-
54. A method according to claim 42, wherein said myeloproliferative disorder is post-essential thrombocythemia myelofibrosis (Post-ET MF).
-
55. A method according to claim 42, wherein said bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, bone resorption associated with hormonal therapy, bone resorption associated with autoimmune disease, or bone resorption associated with cancer.
-
4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are each independently selected from H, —
-
2-3. -3. (canceled)
-
10-21. -21. (canceled)
-
23-25. -25. (canceled)
-
36. (canceled)
-
47. (canceled)
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeIncyte Holdings Corporation And Incyte Corporation
-
Original AssigneeIncyte Corporation
-
InventorsRodgers, James D., Arvanitis, Argyrios G.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/210.18
-
CPC Class CodesA61P 1/00 Drugs for disorders of the ...A61P 13/12 of the kidneysA61P 17/00 Drugs for dermatological di...A61P 19/00 Drugs for skeletal disordersA61P 19/02 for joint disorders, e.g. a...A61P 19/08 for bone diseases, e.g. rac...A61P 19/10 for osteoporosisA61P 21/04 for myasthenia gravisA61P 25/00 Drugs for disorders of the ...A61P 29/00 Non-central analgesic, anti...A61P 3/10 for hyperglycaemia, e.g. an...A61P 35/00 Antineoplastic agentsA61P 35/02 specific for leukemiaA61P 37/00 Drugs for immunological or ...A61P 37/02 ImmunomodulatorsA61P 37/06 Immunosuppressants, e.g. dr...A61P 37/08 Antiallergic agents antiast...A61P 7/00 Drugs for disorders of the ...A61P 9/00 Drugs for disorders of the ...C07D 473/04 two oxygen atomsC07D 487/04 : Ortho-condensed systems